Rana McKay, MD
Rana McKay, MD, is a medical oncologist at the University of California, San Diego Moores Cancer Center.
Articles by Rana McKay, MD
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
Drs. McKay and Rosenberg preview AUC3, the inaugural Advanced Urologic Cancer Consensus Conference.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
The panel shared their excitement for the road ahead in kidney cancer.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.